7ACC2 is a monocarboxylate transporters MCT1 & MCT4 (SLC16A1 & SLC16A3) inhibitor that affects lactate uptake-dependent cancer growth in cultures (uptake/proliferation IC50 = 59/220 nM; MCT1/4-expressing SiHA cervix cancer in the absence of glucose) and in vivo (3 mg/kg/day i.p.; SiHa, HCT116, MCF-7 in mice), without affecting lactate efflux or the survival of highly glycolytic HL-60 (MCT1) or MDA-MB231 (MCT4) cancer cells. Unlike the MCT1/2 inhibitor AR-C155858, 7ACC2 does not block MCT1-mediated uptake of the anti-cancer drug 3-bromopyruvate (3-BP).
Monocarboxylate transporters MCT1 & MCT4 (SLC16A1 & SLC16A3) inhibitor that blocks lactate update-dependent cancer growth in vitro and in vivo.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.